Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade D 1.88 -0.53% -0.01
AEZS closed down 0.53 percent on Friday, February 23, 2018, on 6 percent of normal volume.
8 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical AEZS trend table...

Date Alert Name Type % Chg
Feb 23 Narrow Range Bar Range Contraction 0.00%
Feb 23 Wide Bands Range Expansion 0.00%
Feb 22 Wide Bands Range Expansion -0.53%
Feb 21 Narrow Range Bar Range Contraction 1.08%
Feb 21 Wide Bands Range Expansion 1.08%
Feb 21 Down 3 Days in a Row Weakness 1.08%
Feb 20 Narrow Range Bar Range Contraction 0.00%
Feb 20 NR7 Range Contraction 0.00%
Feb 20 NR7-2 Range Contraction 0.00%
Feb 20 Wide Bands Range Expansion 0.00%

Older signals for AEZS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.75
52 Week Low 0.7816
Average Volume 831,320
200-Day Moving Average 1.8125
50-Day Moving Average 2.1772
20-Day Moving Average 2.0215
10-Day Moving Average 1.896
Average True Range 0.1203
ADX 21.34
+DI 19.53
-DI 30.18
Chandelier Exit (Long, 3 ATRs ) 2.1091
Chandelier Exit (Short, 3 ATRs ) 2.0609
Upper Bollinger Band 2.3399
Lower Bollinger Band 1.7031
Percent B (%b) 0.28
BandWidth 31.50136
MACD Line -0.0959
MACD Signal Line -0.0877
MACD Histogram -0.0083
Fundamentals Value
Market Cap 30.29 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -1.10
Price-to-Sales 28.12
Price-to-Book 6.12
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.97
Resistance 3 (R3) 1.97 1.94 1.96
Resistance 2 (R2) 1.94 1.92 1.94 1.95
Resistance 1 (R1) 1.91 1.90 1.90 1.91 1.94
Pivot Point 1.88 1.88 1.87 1.88 1.88
Support 1 (S1) 1.85 1.86 1.84 1.85 1.82
Support 2 (S2) 1.82 1.84 1.82 1.81
Support 3 (S3) 1.79 1.82 1.81
Support 4 (S4) 1.79